321674-73-1 Usage
Uses
Used in Pharmaceutical Industry:
2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific targeting and therapeutic properties.
Used in Chemical Research:
In the field of chemical research, 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID serves as a valuable compound for studying the properties and reactivity of complex organic molecules. It can be used to explore new reaction pathways and develop innovative synthetic methods.
Used in Material Science:
The unique structure of 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID also makes it a potential candidate for the development of new materials with specific properties. It can be used in the design of advanced materials for various applications, such as optoelectronics, sensors, and coatings.
Used in Dye and Pigment Industry:
Due to its naphthalene-based structure, 2-[[(2E)-3-(2-NAPHTHALENYL)-1-OXO-2-BUTEN-1-YL]AMINO]BENZOIC ACID may have potential applications in the dye and pigment industry. It could be used as a starting material for the synthesis of novel dyes and pigments with unique color properties and stability.
Biological Activity
Selective telomerase inhibitor (IC 50 values are 93, > 100000 and > 100000 nM for human telomerase, human RNA polymerase I and human RNA polymerase II + III respectively). Causes telomere shortening in exponentially growing NCI-H460 lung carcinoma cells and eventual growth arrest.
references
[1]. damm, k.; hemmann, u.; garin-chesa, p.; hauel, n.; kauffman, i.; priepke, h.; niestroj, c.; daiber, c.; enenkel, b.; guilliard, b.; lauritsch, i.; muller, e.; pascolo, e.; sauter, g.; pantic, m.; martens, u. m.; wenz, c.; linger, j.; kraut, n.; rettig, w. j.;schnapp, a. a highly selective telomerase inhibitor limiting human cancer cell proliferation. embo j. 2001, 20, 6958?6968.[2]. bashash d1, ghaffari sh, mirzaee r, alimoghaddam k, ghavamzadeh a. telomerase inhibition by non-nucleosidic compound bibr1532 causes rapid cell death in pre-b acute lymphoblastic leukemia cells. leuk lymphoma. 2013 mar;54[4]:561-8. doi: 10.3109/10428194.2012.704034. epub 2012 sep 28.[3]. bashash d1, ghaffari sh, zaker f, kazerani m, hezave k, hassani s, rostami m, alimoghaddam k, ghavamzadeh a. anticancer agents med chem. 2013 sep;13(7):1115-25. bibr 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for apl.
Check Digit Verification of cas no
The CAS Registry Mumber 321674-73-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,1,6,7 and 4 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 321674-73:
(8*3)+(7*2)+(6*1)+(5*6)+(4*7)+(3*4)+(2*7)+(1*3)=131
131 % 10 = 1
So 321674-73-1 is a valid CAS Registry Number.
InChI:InChI=1/C21H17NO3/c1-14(16-11-10-15-6-2-3-7-17(15)13-16)12-20(23)22-19-9-5-4-8-18(19)21(24)25/h2-13H,1H3,(H,22,23)(H,24,25)/b14-12+
321674-73-1Relevant articles and documents
TELOMERASE REVERSE TRANSCRIPTASE DEGRADERS AND METHODS OF USE THEREOF
-
, (2020/12/30)
The present disclosure provides TERT inhibitor compounds, a TERT inhibitor linked to a ubiquitin ligase ligand, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting telomerase reverse transcriptase (TERT) and methods of treating or preventing a disease or disorder using said compounds and/or compositions.
N-substituted acrylamide derivatives as DHODH inhibitors and preparation and use of N-substituted acrylamide derivatives
-
Paragraph 0178-0179; 0183; 0320-0322, (2019/11/04)
The invention relates to N-substituted acrylamide derivatives as DHODH inhibitors and preparation and use of the N-substituted acrylamide derivatives. In particular, the invention discloses a compoundshown in a general formula I and the preparation and use of the compound. The compound has excellent DHODH inhibitory activation, so the compound can be used for treating or preventing various diseases caused by DHODH, the various diseases include but not limited to cancer, rheumatoid arthritis, lupus erythematosus, organ transplant rejection and other autoimmune diseases, and colitis, rhinitis and other inflammatory diseases.
Inhibition of telomerase by BIBR 1532 and related analogues
Barma,Elayadi, Anissa,Falck,Corey, David R.
, p. 1333 - 1336 (2007/10/03)
BIBR 1532 has been reported to be a potent, small molecule inhibitor of human telomerase, suggesting it as a lead for the development of anti-telomerase therapy. We confirm the ability of BIBR 1532 to inhibit telomerase and report the discovery of an equa
Carboxylic acid amides, pharmaceutical compositions containing these compounds and their use
-
, (2008/06/13)
Carboxylic acid amides of general formula which inhibit telomerase and are useful for treating tumour diseases such as carcinomas, sarcomas and leukaemias. Exemplary compounds are: (1) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide, and, (2) trans-3-(naphth-2-yl)-but-2-enoic acid-N-(2-carboxy-4,5-dimethoxy-phenyl)-amide.
